RE-LY trial
E861731
The RE-LY trial was a large, pivotal clinical study that compared the efficacy and safety of the oral anticoagulant dabigatran with warfarin for stroke prevention in patients with atrial fibrillation.
All labels observed (1)
| Label | Occurrences |
|---|---|
| RE-LY trial canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T10401946 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: RE-LY trial Context triple: [dabigatran, hasClinicalTrial, RE-LY trial]
-
A.
APHINITY trial
The APHINITY trial is a large phase III clinical study that evaluated the addition of pertuzumab (Perjeta) to standard trastuzumab-based adjuvant therapy in patients with HER2-positive early breast cancer.
-
B.
CLEOPATRA trial
The CLEOPATRA trial was a pivotal phase III clinical study that demonstrated improved survival by adding pertuzumab (Perjeta) to trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer.
-
C.
ENGAGE (Study 301)
ENGAGE (Study 301) is a large Phase 3 clinical trial designed to evaluate the efficacy and safety of the anti-amyloid monoclonal antibody aducanumab (Aduhelm) in patients with early Alzheimer’s disease.
-
D.
EMERGE (Study 302)
EMERGE (Study 302) is a pivotal Phase 3 clinical trial designed to evaluate the efficacy and safety of the Alzheimer’s disease drug aducanumab (Aduhelm) in patients with early-stage Alzheimer’s.
-
E.
Jackson Heart Study
The Jackson Heart Study is a large, long-term epidemiological research project focused on understanding cardiovascular disease and its risk factors among African American communities, particularly in Jackson, Mississippi.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: RE-LY trial Target entity description: The RE-LY trial was a large, pivotal clinical study that compared the efficacy and safety of the oral anticoagulant dabigatran with warfarin for stroke prevention in patients with atrial fibrillation.
-
A.
APHINITY trial
The APHINITY trial is a large phase III clinical study that evaluated the addition of pertuzumab (Perjeta) to standard trastuzumab-based adjuvant therapy in patients with HER2-positive early breast cancer.
-
B.
CLEOPATRA trial
The CLEOPATRA trial was a pivotal phase III clinical study that demonstrated improved survival by adding pertuzumab (Perjeta) to trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer.
-
C.
ENGAGE (Study 301)
ENGAGE (Study 301) is a large Phase 3 clinical trial designed to evaluate the efficacy and safety of the anti-amyloid monoclonal antibody aducanumab (Aduhelm) in patients with early Alzheimer’s disease.
-
D.
EMERGE (Study 302)
EMERGE (Study 302) is a pivotal Phase 3 clinical trial designed to evaluate the efficacy and safety of the Alzheimer’s disease drug aducanumab (Aduhelm) in patients with early-stage Alzheimer’s.
-
E.
Jackson Heart Study
The Jackson Heart Study is a large, long-term epidemiological research project focused on understanding cardiovascular disease and its risk factors among African American communities, particularly in Jackson, Mississippi.
- F. None of above. chosen
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
clinical trial
ⓘ
phase III trial ⓘ randomized controlled trial ⓘ |
| acronym | RE-LY NERFINISHED ⓘ |
| anticoagulantMechanismStudied | direct thrombin inhibition ⓘ |
| clinicalQuestion | whether dabigatran can replace warfarin for stroke prevention in atrial fibrillation ⓘ |
| comparatorDrug | warfarin ⓘ |
| comparatorDrugClass | vitamin K antagonist ⓘ |
| controlGroup | dose-adjusted warfarin ⓘ |
| dabigatranDoseArm |
110 mg twice daily
ⓘ
150 mg twice daily ⓘ |
| designFeature |
blinded dabigatran doses
ⓘ
multicenter ⓘ open-label warfarin arm ⓘ prospective ⓘ randomized ⓘ |
| drugClassStudied | direct thrombin inhibitor ⓘ |
| efficacyOutcome |
hemorrhagic stroke
ⓘ
ischemic stroke ⓘ systemic embolism ⓘ |
| enrollmentSize | over 18,000 patients ⓘ |
| fullName | Randomized Evaluation of Long-Term Anticoagulation Therapy NERFINISHED ⓘ |
| geographicScope | international ⓘ |
| impact |
influenced atrial fibrillation stroke prevention guidelines
ⓘ
supported regulatory approval of dabigatran for stroke prevention in atrial fibrillation ⓘ |
| indicationStudied | nonvalvular atrial fibrillation ⓘ |
| interventionDrug | dabigatran etexilate NERFINISHED ⓘ |
| keyFinding |
both dabigatran doses reduced intracranial hemorrhage compared with warfarin
ⓘ
dabigatran 110 mg twice daily had lower major bleeding than warfarin ⓘ dabigatran 110 mg twice daily was noninferior to warfarin for stroke or systemic embolism ⓘ dabigatran 150 mg twice daily increased gastrointestinal bleeding compared with warfarin ⓘ dabigatran 150 mg twice daily reduced stroke or systemic embolism compared with warfarin ⓘ overall mortality was similar or slightly lower with dabigatran compared with warfarin ⓘ |
| patientCondition | increased risk of stroke ⓘ |
| patientPopulation | adult patients ⓘ |
| population | patients with atrial fibrillation at risk of stroke ⓘ |
| primaryEndpoint | stroke or systemic embolism ⓘ |
| primaryObjective | to compare dabigatran with warfarin for stroke prevention in atrial fibrillation ⓘ |
| publicationType | landmark trial in anticoagulation ⓘ |
| resultInterpretation | dabigatran is an effective alternative to warfarin for many patients with atrial fibrillation ⓘ |
| safetyEndpoint | major bleeding ⓘ |
| safetyOutcome |
gastrointestinal bleeding
ⓘ
intracranial hemorrhage ⓘ |
| sponsor | Boehringer Ingelheim NERFINISHED ⓘ |
| therapeuticArea |
cardiology
ⓘ
thrombosis and hemostasis ⓘ |
| warfarinTargetINR | 2.0–3.0 ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: RE-LY trial Description of subject: The RE-LY trial was a large, pivotal clinical study that compared the efficacy and safety of the oral anticoagulant dabigatran with warfarin for stroke prevention in patients with atrial fibrillation.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.